德国CKD队列:血清afamin浓度与肾衰竭的关联
本研究基于德国慢性肾脏病(GCKD)队列5041例白人患者,随访6.5年,探讨血清afamin浓度与肾功能及肾衰竭的关联。结果显示,afamin浓度每升高10mg/L,eGFR高2.60mL/min/1.73m2,UACR低5.97mg/g,肾衰竭风险降低14%。
要点
- 血清afamin浓度较高与更好的肾功能(更高eGFR、更低UACR)独立相关。
- afamin每升高10mg/L,肾衰竭风险降低14%(HR 0.86)。
- afamin可能作为CKD患者肾功能恶化的潜在生物标志物。
核心结论
- 在CKD患者中,较高的血清afamin浓度与更高的eGFR、更低的白蛋白尿及更低的未来肾衰竭风险相关。
研究设计与样本
- 前瞻性队列研究,随访6.5年,纳入德国慢性肾脏病(GCKD)研究中的5041例白人患者。
- 入组条件为eGFR 30-60mL/min/1.73m2,或eGFR>60mL/min/1.73m2且UACR≥300mg/g。
主要发现
- 研究入组时平均afamin浓度为73.2±17.6mg/L。
- 校正分析中,afamin浓度每升高10mg/L,eGFR高2.60mL/min/1.73m2(95% CI 2.30-2.89),UACR低5.97mg/g(95% CI 3.04-8.90)。
- 随访期间,afamin浓度每升高10mg/L,肾衰竭风险降低14%(HR 0.86,95% CI 0.81-0.92,P<0.001)。
临床怎么用
- 血清afamin浓度或可用于CKD患者肾功能恶化风险的评估,但需进一步验证。
局限性
- 存在残余混杂。
- 结果可能不适用于非白人人群及轻度CKD或无CKD人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Afamin is a vitamin E-binding glycoprotein primarily expressed in the liver and kidney. This study investigated whether serum afamin concentrations are associated with kidney function and incident kidney failure. STUDY DESIGN: Prospective cohort study with 6.5 years follow-up. SETTING & PARTICIPANTS: 5,041 White patients enrolled in the German Chronic Kidney Disease (GCKD) study with measured afamin concentrations and either an estimated glomerular filtration rate (eGFR) of 30-60mL/min/1.73m2 or an eGFR>60mL/min/1.73m2 with a urinary albumin-creatinine ratio (UACR) of≥300mg/g at study entry. EXPOSURE: Serum afamin concentrations (mg/L). OUTCOME: Incident kidney failure (initiation of kidney replacement therapy or kidney-related death). ANALYTICAL APPROACH: Generalized linear regression and quantile regression models fit to investigate the association of afamin concentrations with eGFR and UACR. Adjusted Cox regression analysis to examine the association of afamin concentrations with incident kidney failure. RESULTS: The mean±SD afamin concentration at study entry was 73.2±17.6mg/L. Higher afamin concentrations were associated with better kidney function with a 2.60mL/min/1.73m2 higher eGFR (95% CI, 2.30-2.89) and a 5.97mg/g lower UACR (95% CI, 3.04-8.90) for each 10mg/L higher level of afamin concentration in adjusted analysis. During the follow-up period, each 10mg/L higher level of afamin concentration was associated with a 14% lower risk of kidney failure (HR, 0.86 [95%CI, 0.81-0.92], P<0.001). LIMITATIONS: Residual confounding, and potential limited generalizability to non-White populations and people with mild stages of chronic kidney disease (CKD) or no CKD. CONCLUSIONS: Higher serum afamin concentrations appear to be associated with a higher eGFR, less albuminuria, and a lower risk for future kidney failure in patients with CKD.
引用
- Kollerits B, Kotsis F, Schneider MP, et al. Association of Serum Afamin Concentrations With Kidney Failure in Patients With CKD: Findings From the German CKD Cohort Study. Am J Kidney Dis. 2024. PMID: 39743167. doi:10.1053/j.ajkd.2024.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。